Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Landauer, Inc. Reaffirms FY 2012 Revenue And Net Income Guidance; Raises FY 2012 EBITDA Guidance


Monday, 7 May 2012 04:38pm EDT 

Landauer, Inc. announced that for fiscal 2012, it continues to anticipate aggregate revenue to be in the range of $150 to $157 million, which includes 10 months of contributions from the recent IZI Medical Products acquisition. The Company anticipates reported net income to be in the range of $21 to $23 million and Adjusted EBITDA in the range of $53 to $57 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $153 million and EBITDA of $49 million for fiscal 2012. 

Company Quote

42.54
-0.18 -0.42%
17 Apr 2014